Why in news?
India’s National Pharmaceutical Pricing Authority (NPPA) allowed a one‑time 50 per cent increase in the ceiling price of two chemotherapy drugs — cisplatin and carboplatin. The regulator invoked special provisions of the Drugs Prices Control Order to prevent shortages caused by a steep rise in platinum prices. Patients rely on these drugs to treat ovarian, lung and bladder cancers.
Background
The NPPA was established in 1997 to ensure affordable medicines while allowing reasonable profits. Its functions include fixing prices of scheduled drugs, monitoring availability and enforcing legal provisions. Platinum, a key input for certain chemotherapy drugs, has become expensive due to global supply disruptions. Shortages in India forced some patients to shift to costlier alternatives.
Key details
- The price of cisplatin rose from ₹ 7.26 to ₹ 10.89 per millilitre.
- Carboplatin’s ceiling price increased from ₹ 60.49 to ₹ 90.74 per millilitre.
- The hike is temporary and will be reviewed after six months.
- NPPA also revised prices of some vaccines and extended advisory on essential medicines.
Conclusion
By raising the ceiling prices, the NPPA hopes to maintain supplies of vital cancer drugs despite volatile raw material costs. The step underscores the regulator’s role in balancing public health needs with industry realities.
Source: The Hindu